Immunomodulatory Drug CC-5013 Overcomes Drug ... - PubMed

Clipboard, Search History, and several other advanced features are temporarily unavailable. Skip to main page content

The .gov means it’s official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

The site is secure. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation Search: Search Advanced Clipboard Save Email Send to

• Clipboard
• My Bibliography
• Collections
• Citation manager

Display options Display options Format Abstract PubMed PMID

Save citation to file

Format: Summary (text) PubMed PMID Abstract (text) CSV Create file Cancel

Email citation

Subject: 1 selected item: 12384400 - PubMed To: From: Format: Summary Summary (text) Abstract Abstract (text) MeSH and other data Send email Cancel

Add to Collections

• Create a new collection
• Add to an existing collection

Name your collection: Name must be less than 100 characters Choose a collection: Unable to load your collection due to an error Please try again Add Cancel

Add to My Bibliography

• My Bibliography

Unable to load your delegates due to an error Please try again Add Cancel

Your saved search

Name of saved search: Search terms: Test search terms Would you like email updates of new search results? Saved Search Alert Radio Buttons

• Yes
• No

Email: (change) Frequency: Monthly Weekly Daily Which day? The first Sunday The first Monday The first Tuesday The first Wednesday The first Thursday The first Friday The first Saturday The first day The first weekday Which day? Sunday Monday Tuesday Wednesday Thursday Friday Saturday Report format: Summary Summary (text) Abstract Abstract (text) PubMed Send at most: 1 item 5 items 10 items 20 items 50 items 100 items 200 items Send even when there aren't any new results Optional text in email: Save Cancel

Create a file for external citation management software

Create file Cancel

Your RSS Feed

Name of RSS Feed: Number of items displayed: 5 10 15 20 50 100 Create RSS Cancel RSS Link Copy

Full text links

Silverchair Information Systems Elsevier Science Full text links

Actions

CiteCollectionsAdd to Collections

• Create a new collection
• Add to an existing collection

Name your collection: Name must be less than 100 characters Choose a collection: Unable to load your collection due to an errorPlease try again Add Cancel Display options Display options Format AbstractPubMedPMID

Share

• Permalink Copy

Page navigation

• Title & authors
• Abstract
• Similar articles
• Cited by
• Publication types
• MeSH terms
• Substances
• Related information
• Grants and funding
• LinkOut - more resources

Title & authors Abstract Similar articles Cited by Publication types MeSH terms Substances Related information Grants and funding LinkOut - more resources Full text links CiteDisplay options Display options Format AbstractPubMedPMID

Abstract

Thalidomide (Thal) can overcome drug resistance in multiple myeloma (MM) but is associated with somnolence, constipation, and neuropathy. In previous in vitro studies, we have shown that the potent immunomodulatory derivative of thalidomide (IMiD) CC-5013 induces apoptosis or growth arrest even in resistant MM cell lines and patient cells, decreases binding of MM cells to bone marrow stromal cells (BMSCs), inhibits the production in the BM milieu of cytokines (interleukin-6 [IL-6], vascular endothelial growth factor [VEGF], tumor necrosis factor-alpha [TNF-alpha]) mediating growth and survival of MM cells, blocks angiogenesis, and stimulates host anti-MM natural killer (NK) cell immunity. Moreover, CC-5013 also inhibits tumor growth, decreases angiogenesis, and prolongs host survival in a human plasmacytoma mouse model. In the present study, we carried out a phase 1 CC-5013 dose-escalation (5 mg/d, 10 mg/d, 25 mg/d, and 50 mg/d) study in 27 patients (median age 57 years; range, 40-71 years) with relapsed and refractory relapsed MM. They received a median of 3 prior regimens (range, 2-6 regimens), including autologous stem cell transplantation and Thal in 15 and 16 patients, respectively. In 24 evaluable patients, no dose-limiting toxicity (DLT) was observed in patients treated at any dose level within the first 28 days; however, grade 3 myelosuppression developed after day 28 in all 13 patients treated with 50 mg/d CC-5013. In 12 patients, dose reduction to 25 mg/d was well tolerated and therefore considered the maximal tolerated dose (MTD). Importantly, no significant somnolence, constipation, or neuropathy has been seen in any cohort. Best responses of at least 25% reduction in paraprotein occurred in 17 (71%) of 24 patients (90% confidence interval [CI], 52%-85%), including 11 (46%) patients who had received prior Thal. Stable disease (less than 25% reduction in paraprotein) was observed in an additional 2 (8%) patients. Therefore, 17 (71%) of 24 patients (90% CI, 52%-85%) demonstrated benefit from treatment. Our study therefore provides the basis for the evaluation of CC-5013, either alone or in combination, to treat patients with MM at earlier stages of disease.

PubMed Disclaimer

Similar articles

• The role of immunomodulatory drugs in multiple myeloma. Anderson KC. Anderson KC. Semin Hematol. 2003 Oct;40(4 Suppl 4):23-32. doi: 10.1053/j.seminhematol.2003.09.010. Semin Hematol. 2003. PMID: 15015893 Review.
• Thalidomide and CC-5013 in multiple myeloma: the University of Arkansas experience. Barlogie B. Barlogie B. Semin Hematol. 2003 Oct;40(4 Suppl 4):33-8. doi: 10.1053/j.seminhematol.2003.09.005. Semin Hematol. 2003. PMID: 15015894 Review.
• Bortezomib, thalidomide, dexamethasone, and panobinostat for patients with relapsed multiple myeloma (MUK-six): a multicentre, open-label, phase 1/2 trial. Popat R, Brown SR, Flanagan L, Hall A, Gregory W, Kishore B, Streetly M, Oakervee H, Yong K, Cook G, Low E, Cavenagh J; Myeloma UK Early Phase Clinical Trial Network. Popat R, et al. Lancet Haematol. 2016 Dec;3(12):e572-e580. doi: 10.1016/S2352-3026(16)30165-X. Epub 2016 Nov 12. Lancet Haematol. 2016. PMID: 27843120 Clinical Trial.
• Novel therapies targeting the myeloma cell and its bone marrow microenvironment. Hideshima T, Chauhan D, Podar K, Schlossman RL, Richardson P, Anderson KC. Hideshima T, et al. Semin Oncol. 2001 Dec;28(6):607-12. doi: 10.1016/s0093-7754(01)90033-8. Semin Oncol. 2001. PMID: 11740818 Review.
• Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial. Richardson PG, Oriol A, Beksac M, Liberati AM, Galli M, Schjesvold F, Lindsay J, Weisel K, White D, Facon T, San Miguel J, Sunami K, O'Gorman P, Sonneveld P, Robak P, Semochkin S, Schey S, Yu X, Doerr T, Bensmaine A, Biyukov T, Peluso T, Zaki M, Anderson K, Dimopoulos M; OPTIMISMM trial investigators. Richardson PG, et al. Lancet Oncol. 2019 Jun;20(6):781-794. doi: 10.1016/S1470-2045(19)30152-4. Epub 2019 May 13. Lancet Oncol. 2019. PMID: 31097405 Clinical Trial.

See all similar articles

Cited by

• Lenalidomide-induced pure red cell aplasia is associated with elevated expression of MHC-I molecules on erythrocytes. Hu Q, Liu Y, Yue Q, Zhou S, Jin X, Lin F, Huang XJ, Zhuang J, Lu J, Gao X, Lee HY. Hu Q, et al. Nat Commun. 2024 Nov 22;15(1):10131. doi: 10.1038/s41467-024-54571-w. Nat Commun. 2024. PMID: 39578482 Free PMC article.
• Cytidine triphosphate synthase 1-mediated metabolic reprogramming promotes proliferation and drug resistance in multiple myeloma. Huang H, Chen Y, Li Y, Zheng X, Shu L, Tian L, Lin H, Liang Y. Huang H, et al. Heliyon. 2024 Jun 20;10(13):e33001. doi: 10.1016/j.heliyon.2024.e33001. eCollection 2024 Jul 15. Heliyon. 2024. PMID: 39050461 Free PMC article.
• Quantitative Integrative Survival Prediction in Multiple Myeloma Patients Treated With Bortezomib-Based Induction, High-Dose Therapy and Autologous Stem Cell Transplantation. Hummel M, Hielscher T, Emde-Rajaratnam M, Salwender H, Beck S, Scheid C, Bertsch U, Goldschmidt H, Jauch A, Moreaux J, Seckinger A, Hose D. Hummel M, et al. JCO Precis Oncol. 2024 Jul;8:e2300613. doi: 10.1200/PO.23.00613. JCO Precis Oncol. 2024. PMID: 38986047 Free PMC article.
• Molecular Long-Term Analysis of the GMMG-HD4 Trial in Multiple Myeloma-Patterns of Association of Chromosomal Aberrations with Response and Proliferation Determining Survival in Selecting Treatments in View of Limited Resources in Low- and Middle-Income Countries. Seckinger A, Salwender H, Martin H, Scheid C, Hielscher T, Bertsch U, Hummel M, Jauch A, Knauf W, Emde-Rajaratnam M, Beck S, Neben K, Dührig J, Lindemann W, Schmidt-Wolf IGH, Hänel M, Blau IW, Weisel K, Weinhold N, Raab MS, Goldschmidt H, Choon-Quinones M, Hose D. Seckinger A, et al. Int J Mol Sci. 2024 Jun 11;25(12):6431. doi: 10.3390/ijms25126431. Int J Mol Sci. 2024. PMID: 38928138 Free PMC article. Clinical Trial.
• RNA-sequencing based first choice of treatment and determination of risk in multiple myeloma. Emde-Rajaratnam M, Beck S, Benes V, Salwender H, Bertsch U, Scheid C, Hänel M, Weisel K, Hielscher T, Raab MS, Goldschmidt H, Jauch A, Maes K, De Bruyne E, Menu E, De Veirman K, Moreaux J, Vanderkerken K, Seckinger A, Hose D. Emde-Rajaratnam M, et al. Front Immunol. 2023 Nov 15;14:1286700. doi: 10.3389/fimmu.2023.1286700. eCollection 2023. Front Immunol. 2023. PMID: 38035078 Free PMC article.

See all "Cited by" articles

Publication types

• Clinical Trial Actions
  • Search in PubMed
  • Search in MeSH
  • Add to Search
• Clinical Trial, Phase I Actions
  • Search in PubMed
  • Search in MeSH
  • Add to Search
• Research Support, Non-U.S. Gov't Actions
  • Search in PubMed
  • Search in MeSH
  • Add to Search
• Research Support, U.S. Gov't, P.H.S. Actions
  • Search in PubMed
  • Search in MeSH
  • Add to Search

MeSH terms

• Adjuvants, Immunologic / administration & dosage Actions
  • Search in PubMed
  • Search in MeSH
  • Add to Search
• Adjuvants, Immunologic / adverse effects Actions
  • Search in PubMed
  • Search in MeSH
  • Add to Search
• Adjuvants, Immunologic / pharmacokinetics Actions
  • Search in PubMed
  • Search in MeSH
  • Add to Search
• Adjuvants, Immunologic / pharmacology Actions
  • Search in PubMed
  • Search in MeSH
  • Add to Search
• Adjuvants, Immunologic / therapeutic use* Actions
  • Search in PubMed
  • Search in MeSH
  • Add to Search
• Administration, Oral Actions
  • Search in PubMed
  • Search in MeSH
  • Add to Search
• Adult Actions
  • Search in PubMed
  • Search in MeSH
  • Add to Search
• Aged Actions
  • Search in PubMed
  • Search in MeSH
  • Add to Search
• Antineoplastic Combined Chemotherapy Protocols / therapeutic use Actions
  • Search in PubMed
  • Search in MeSH
  • Add to Search
• Apoptosis / drug effects Actions
  • Search in PubMed
  • Search in MeSH
  • Add to Search
• Combined Modality Therapy Actions
  • Search in PubMed
  • Search in MeSH
  • Add to Search
• Constipation / chemically induced Actions
  • Search in PubMed
  • Search in MeSH
  • Add to Search
• Dose-Response Relationship, Drug Actions
  • Search in PubMed
  • Search in MeSH
  • Add to Search
• Drug Resistance, Neoplasm* Actions
  • Search in PubMed
  • Search in MeSH
  • Add to Search
• Female Actions
  • Search in PubMed
  • Search in MeSH
  • Add to Search
• Humans Actions
  • Search in PubMed
  • Search in MeSH
  • Add to Search
• Lenalidomide Actions
  • Search in PubMed
  • Search in MeSH
  • Add to Search
• Male Actions
  • Search in PubMed
  • Search in MeSH
  • Add to Search
• Maximum Tolerated Dose Actions
  • Search in PubMed
  • Search in MeSH
  • Add to Search
• Middle Aged Actions
  • Search in PubMed
  • Search in MeSH
  • Add to Search
• Multiple Myeloma / drug therapy* Actions
  • Search in PubMed
  • Search in MeSH
  • Add to Search
• Multiple Myeloma / immunology Actions
  • Search in PubMed
  • Search in MeSH
  • Add to Search
• Myeloma Proteins / analysis Actions
  • Search in PubMed
  • Search in MeSH
  • Add to Search
• Nervous System Diseases / chemically induced Actions
  • Search in PubMed
  • Search in MeSH
  • Add to Search
• Neutropenia / chemically induced Actions
  • Search in PubMed
  • Search in MeSH
  • Add to Search
• Peripheral Blood Stem Cell Transplantation Actions
  • Search in PubMed
  • Search in MeSH
  • Add to Search
• Remission Induction Actions
  • Search in PubMed
  • Search in MeSH
  • Add to Search
• Safety Actions
  • Search in PubMed
  • Search in MeSH
  • Add to Search
• Salvage Therapy* Actions
  • Search in PubMed
  • Search in MeSH
  • Add to Search
• Thalidomide / administration & dosage Actions
  • Search in PubMed
  • Search in MeSH
  • Add to Search
• Thalidomide / adverse effects Actions
  • Search in PubMed
  • Search in MeSH
  • Add to Search
• Thalidomide / analogs & derivatives Actions
  • Search in PubMed
  • Search in MeSH
  • Add to Search
• Thalidomide / pharmacokinetics Actions
  • Search in PubMed
  • Search in MeSH
  • Add to Search
• Thalidomide / pharmacology Actions
  • Search in PubMed
  • Search in MeSH
  • Add to Search
• Thalidomide / therapeutic use* Actions
  • Search in PubMed
  • Search in MeSH
  • Add to Search
• Thrombocytopenia / chemically induced Actions
  • Search in PubMed
  • Search in MeSH
  • Add to Search
• Transplantation, Autologous Actions
  • Search in PubMed
  • Search in MeSH
  • Add to Search
• Treatment Outcome Actions
  • Search in PubMed
  • Search in MeSH
  • Add to Search

Substances

• Adjuvants, Immunologic Actions
  • Search in PubMed
  • Search in MeSH
  • Add to Search
• Myeloma Proteins Actions
  • Search in PubMed
  • Search in MeSH
  • Add to Search
• Thalidomide Actions
  • Search in PubMed
  • Search in MeSH
  • Add to Search
• Lenalidomide Actions
  • Search in PubMed
  • Search in MeSH
  • Add to Search

Related information

• Cited in Books
• PubChem Compound
• PubChem Compound (MeSH Keyword)
• PubChem Substance

Grants and funding

• P0-78378/PHS HHS/United States
• R01 50947/PHS HHS/United States

LinkOut - more resources

• Full Text Sources

  • Elsevier Science
  • Silverchair Information Systems

• Other Literature Sources

  • The Lens - Patent Citations Database

• Medical

  • MedlinePlus Health Information

Full text links [x] Silverchair Information Systems Elsevier Science [x] Cite Copy Download .nbib .nbib Format: AMA APA MLA NLM Send To

• Clipboard
• Email
• Save
• My Bibliography
• Collections
• Citation Manager

[x]

NCBI Literature Resources

MeSH PMC Bookshelf Disclaimer

The PubMed wordmark and PubMed logo are registered trademarks of the U.S. Department of Health and Human Services (HHS). Unauthorized use of these marks is strictly prohibited.